Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.40 |
| ▸ | JAK1 | P23458 | 6/20 | 0.40 |
| ▸ | TYK2 | P29597 | 6/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21048878 | 0.85 | JAK2 (0.44) | ALDH1A1TP53JAK2JAK1TYK2 | |
| SCHEMBL19337065 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TP53JAK2JAK1TYK2 | |
| SCHEMBL21048978 | 0.82 | TP53 (0.52) | ALDH1A1TP53JAK2JAK1TYK2 | |
| SCHEMBL21048857 | 0.80 | HTT (0.39) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1291494 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TP53JAK2JAK1TYK2 | |
| SCHEMBL14479721 | 0.80 | CLK2 (0.49) | ALDH1A1JAK2JAK3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL21048863 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TP53JAK2JAK1TYK2 | |
| SCHEMBL21048808 | 0.76 | TP53 (0.44) | TP53JAK2JAK1TYK2JAK3 | |
| SCHEMBL19337154 | 0.74 | ALDH1A1 (0.59) | ALDH1A1TP53MEN1KMT2ALMNA | |
| SCHEMBL1291148 | 0.73 | ESR1 (0.60) | ALDH1A1MEN1KMT2AHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | ALDH1A1 2993/4885TP53 527/4885JAK2 78/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | ALDH1A1 3745/4885TP53 913/4885JAK2 501/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | ALDH1A1 3745/4885TP53 913/4885JAK2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.